Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study
Integrating spatial profiling, single-cell technologies and blood-based correlates may help reveal why immunotherapy is effective in some tumours but not others
2025 ESMO Immuno-Oncology Awardee, Ignacio Melero, is confident that combinations and novel multispecific agents will result in synergistic strategies to ensure the continued success of cancer immunotherapy
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy
Blocking GDF-15, an mRNA-based therapy and targeting VISTA have a strong mechanistic rationale, resulting in clinical benefit in heavily pre-treated patients
Despite the presentation of encouraging study findings with novel immunotherapy-based therapies, long-term outcomes are needed to better understand the magnitude of clinical benefit and many questions remain around off-target toxicity and the identification of patients most likely to respond to treatment
Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.